dupilumab
sanofi,regeneron
['derm', 'regeneron', 'sanofi']
at #aad2023, we re presenting late-breaking positive results from a phase 3 trial in adults and adolescents with #atopicdermatitis of the hands and feet, a particularly difficult-to-treat form of the disease. 
Official channel for Regeneron. We turn science into medicine for people with serious diseases. View our terms of engagement here https://t.co/EuFDUdQQ5E